Palvella Therapeutics, Inc.

Late-stage rare-disease company building a portfolio of first-in-disease therapies for serious skin and vascular malformation conditions, anchored by the QTORIN topical rapamycin platform. Lead program QTORIN rapamycin (SELVA Phase 3) hit primary and all key secondary endpoints in microcystic lymphatic malformations (mLM-IGA mean change +2.13, p<0.001) and is positioned to be the first FDA-approved therapy for the indication; the GASLIGHT trial extends QTORIN into cutaneous venous malformations.